Temsirolimus
- CAS No.
- 162635-04-3
- Chemical Name:
- Temsirolimus
- Synonyms
- 40-[3-Hydroxy-2-(hydroxymethyl)-2-methylpropanoate]-rapamycin;C15182;CS-442;CCL-779;NSC 683864;TEMSIROLIMUS;Simultaneous;TeMsiroliMus (~90%);Temsirolimus, >=98%;CCI-779; NSC 683864
- CBNumber:
- CB3506811
- Molecular Formula:
- C56H87NO16
- Molecular Weight:
- 1030.29
- MOL File:
- 162635-04-3.mol
- MSDS File:
- SDS
- Modify Date:
- 2024/4/22 13:28:10
| Melting point | 99-101°C |
|---|---|
| Boiling point | 1048.4±75.0 °C(Predicted) |
| Density | 1.21 |
| Flash point | 587.8℃ |
| storage temp. | room temp |
| solubility | Soluble in chloroform, methanol. |
| pka | 10.40±0.70(Predicted) |
| form | powder |
| color | white to off-white |
| Merck | 14,9142 |
| InChIKey | CBPNZQVSJQDFBE-FUXHJELOSA-N |
SAFETY
Risk and Safety Statements
| Symbol(GHS) |  GHS08 |
|||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Signal word | Danger | |||||||||
| Hazard statements | H360-H413 | |||||||||
| Precautionary statements | P501-P273-P202-P201-P280-P308+P313-P405 | |||||||||
| Safety Statements | 24/25 | |||||||||
| WGK Germany | 3 | |||||||||
| RTECS | VE6257000 | |||||||||
| HS Code | 29349990 | |||||||||
| NFPA 704 |
|
Temsirolimus price More Price(3)
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| Sigma-Aldrich(India) | PZ0020 | Temsirolimus ≥98% (HPLC) | 162635-04-3 | 5MG | ₹14115.8 | 2022-06-14 | Buy |
| Sigma-Aldrich(India) | PZ0020 | Temsirolimus ≥98% (HPLC) | 162635-04-3 | 25MG | ₹51732.68 | 2022-06-14 | Buy |
| TCI Chemicals (India) | T3574 | Temsirolimus | 162635-04-3 | 50MG | ₹17600 | 2022-05-26 | Buy |
Temsirolimus Chemical Properties,Uses,Production
Description
While renal cell carcinoma (RCC) accounts for only 2 3% of all cancers, the 5-year survival rate for advanced RCC disease is only 5 10%, with approximately 13,000 deaths occurring annually (US statistics only). Immunotherapeutic cytokine options, such as IFN-αand IL-2, have traditionally been frontline treatments, but these agents are not efficacious in all patients and can cause serious side effects. In addition, bevacizumab, a monoclonal antibody against VEGF, has also demonstrated prolongation of PFS. The newest entry for this indication focuses on targets that are downstream from VEGF. Temsirolimus is an inhibitor of the serine/threonine kinase mTOR, which is the mammalian target of rapamycin. mTOR has been implicated in cell replication through control of the cell cycle translation of specific mRNAs. Inhibition of mTOR prevents phosphorylation of the 4E binding protein-1 and the 40S ribosomal protein S6 kinase that are responsible for cell cycle protein translation initiation; cell cycle arrest occurs as the result of termination of cell division from the G1 to the S phase. Disruption of mTOR signaling also has antiangiogenic effects that could be deemed essential in combating RCC, which is driven by unregulated angiogenesis. Temsirolimus is the 2,2-bis(hydroxymethyl)propionate ester of rapamycin (sirolimus), a macrolide fungicide isolated from the bacteria Streptomyces hygroscopicus. Similar to its parent sirolimus, temsirolimus interacts with mTOR through its complex with FK-506 binding protein 12.
Chemical Properties
White Solid
Uses
Temsirolimus, a cell cycle inhibitor developed by Wyeth for the treatment of renal cell carcinoma, was launched in the US in 2007. Temsirolimus works by inhibiting mTOR (mammalian target of rapamycin)-driven cell proliferation. Temsirolimus is also being developed for the treatment of mantle cell lymphoma (PhIII) and also as mono- or combination therapy for the treatment of ovarian and endometrium cancer (PhII). Additionally, temsirolimus is being evaluated for the treatment of several other types of cancer as well as multiple sclerosis and rheumatoid arthritis.
General Description
Temsirolimus is an esterified derivative of rapamycinand in a similar manner binds initially to the proteinFKBP-12(FK506-binding protein).This complexthen acts to inhibit the mammalian target of rapamycin(mTOR), a serine-threonine kinase that plays a crucial rolein cell division. It is somewhat unique in its method of kinaseinhibition, because it actually binds to an allostericmodulator of the kinase rather than just binding to theATP-binding site like most other kinase inhibitors.Temsirolimus is available as a 25-mg/mL injection forIV administration in the treatment of advanced RCC. Theagent is extensively metabolized and undergoes rapid hydrolysisof the ester function to give rapamycin that retainsactivity.Additional metabolism is mediated primarilyby CYP3A4 to give several hydroxylated and demethylatedmetabolites that are inactive. The agent and metabolites areeliminated primarily in the feces with half-lives of 17 and55 hours for temsirolimus and rapamycin, respectively.This agent, like rapamycin, possesses immunosuppressantproperties and there is an increased risk of infection.The most serious side effects are interstitial lung disease,perforation of the bowel, and acute renal failure althoughthese occur only rarely. The most commonly seen side effects are rash, weakness, mucositis, nausea, edema, andanorexia.
Temsirolimus Preparation Products And Raw materials
Raw materials
Preparation Products
| Supplier | Tel | Country | ProdList | Advantage | Inquiry |
|---|---|---|---|---|---|
| Ralington Pharma | +91-7948911722 +91-9687771722 | Gujarat, India | 1350 | 58 | Inquiry |
| Fresenius Kabi Oncology Limited | +91-1243325000 +91-1244885000 | Haryana, India | 22 | 58 | Inquiry |
| Concord Biotech Limited | +91-2714398200 +91-2714398200 | Gujarat, India | 22 | 58 | Inquiry |
| TCI Chemicals (India) Pvt. Ltd. | 1800 425 7889 | New Delhi, India | 6778 | 58 | Inquiry |
| SUN PHARMACEUTICAL INDUSTRIES LTD | (+91 22) 4324 4324 | New Delhi, India | 175 | 58 | Inquiry |
| BIOCON LTD | +91 80 2808 2808 | New Delhi, India | 39 | 58 | Inquiry |
| CONCORD BIOTECH LTD | +91 79 68138700 | New Delhi, India | 18 | 58 | Inquiry |
| CLEARSYNTH LABS LTD. | +91-22-45045900 | Hyderabad, India | 6351 | 58 | Inquiry |
| A.J Chemicals | 91-9810153283 | New Delhi, India | 6124 | 58 | Inquiry |
| SynZeal Research Pvt Ltd | +1 226-802-2078 | Gujarat, India | 6522 | 58 | Inquiry |
| Supplier | Advantage |
|---|---|
| Ralington Pharma | 58 |
| Fresenius Kabi Oncology Limited | 58 |
| Concord Biotech Limited | 58 |
| TCI Chemicals (India) Pvt. Ltd. | 58 |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 58 |
| BIOCON LTD | 58 |
| CONCORD BIOTECH LTD | 58 |
| CLEARSYNTH LABS LTD. | 58 |
| A.J Chemicals | 58 |
| SynZeal Research Pvt Ltd | 58 |
162635-04-3(Temsirolimus)Related Search:
1of4
chevron_right